抗体医薬品の現状と今後

• Published in: 日本薬理学会年会要旨集 p. 2-S23-2
• Main Author: 金子, 悦士
• Format: Journal Article
• Language: Japanese
• Published: 公益社団法人 日本薬理学会 2022
• Subjects: antibody
• ISSN: 2435-4953
• DOI: 10.1254/jpssuppl.95.0_2-S23-2

Antibodies play an important role in the defense mechanism of the body by inducing antigen neutralization, complement-dependent cytotoxicity, or antibody-dependent cellular cytotoxicity / phagocytosis, to eliminate pathogens. Antibody therapeutics utilize the high specificity in antigen recognition and the originally equipped functions of the antibody. Since the first therapeutic antibody OKT3 was approved in 1986, more than 100 drugs have been approved and used in clinical practice. Antibody therapeutics have continued to evolve since its emergence, and at present, could be considered as a mature platform technology in the pharmaceutical industry. Antigenicity, one of the initial challenges in antibody therapeutics, were resolved as chimerization, humanization, and fully human antibody production technology were established. Attempts to enhance the effector function of the antibody, and in recent years, antibody-drug conjugates or bispecific antibodies have been developed. In this presentation, while looking back on the history and touching on recent topics, the future development of antibody therapeutics will be discussed.